|
WO2009091531A2
(en)
*
|
2008-01-16 |
2009-07-23 |
The General Hospital Corporation |
Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
|
|
US8754190B2
(en)
|
2010-05-05 |
2014-06-17 |
Prolynx Llc |
Controlled release from macromolecular conjugates
|
|
SI2729179T1
(sl)
|
2011-06-06 |
2021-01-29 |
Starpharma Pty Ltd |
Makromolekule
|
|
MX358840B
(es)
*
|
2011-09-07 |
2018-09-05 |
Prolynx Llc |
Hidrogeles con reticulación biodegradable.
|
|
WO2013036857A1
(en)
*
|
2011-09-07 |
2013-03-14 |
Prolynx Llc |
Sulfone linkers
|
|
JP6290187B2
(ja)
*
|
2012-05-11 |
2018-03-07 |
クランツ，アレクサンダー |
癌の処置のためのタンパク質の部位特異的標識及び標的送達
|
|
WO2014116717A1
(en)
*
|
2013-01-22 |
2014-07-31 |
Prolynx Llc |
Sealants having controlled degradation
|
|
WO2014205126A1
(en)
|
2013-06-19 |
2014-12-24 |
The Regents Of The University Of California |
Chemical structures for localized delivery of therapeutic agents
|
|
WO2015061503A1
(en)
*
|
2013-10-22 |
2015-04-30 |
Prolynx Llc |
Conjugates of somatostatin and its analogs
|
|
US11116847B2
(en)
*
|
2013-12-19 |
2021-09-14 |
Seagen Inc. |
Methylene carbamate linkers for use with targeted-drug conjugates
|
|
EP3116525B1
(en)
|
2014-03-14 |
2021-06-23 |
The Regents of the University of California |
Tco conjugates and methods for delivery of therapeutic agents
|
|
WO2017118703A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with low initial npr-b activity
|
|
EP4162955A1
(en)
|
2016-01-08 |
2023-04-12 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with carrier attachment at the ring moiety
|
|
US11311604B2
(en)
|
2016-01-08 |
2022-04-26 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low NPR-C binding
|
|
IL259659B
(en)
|
2016-01-08 |
2022-08-01 |
Ascendis Pharma Growth Disorders As |
Controlled-release cnp agonists with increased nep stability
|
|
EP3400020A1
(en)
|
2016-01-08 |
2018-11-14 |
Ascendis Pharma Growth Disorders A/S |
Cnp prodrugs with large carrier moieties
|
|
CA3008017C
(en)
|
2016-01-08 |
2024-01-02 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
|
KR102786270B1
(ko)
*
|
2016-03-01 |
2025-03-24 |
아센디스 파마 본 디지즈 에이/에스 |
Pth 프로드럭
|
|
KR20180129825A
(ko)
|
2016-03-16 |
2018-12-05 |
프로린크스 엘엘시 |
엑세나타이드 유사체의 연장된 방출 컨쥬게이트
|
|
AU2017295938C1
(en)
|
2016-07-13 |
2021-10-07 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
|
CA3037444A1
(en)
|
2016-09-29 |
2018-04-05 |
Ascendis Pharma Bone Diseases A/S |
Incremental dose finding in controlled-release pth compounds
|
|
BR112019005351A2
(pt)
|
2016-09-29 |
2019-06-11 |
Ascendis Pharma Growth Disorders As |
terapia combinada com agonistas de cnp de liberação controlada
|
|
KR20230170810A
(ko)
|
2016-09-29 |
2023-12-19 |
아센디스 파마 본 디지즈 에이/에스 |
낮은 피크 대 트로프 비를 가진 pth 화합물
|
|
CN109789189B
(zh)
|
2016-09-29 |
2024-01-23 |
阿森迪斯药物骨疾病股份有限公司 |
控释pth化合物的剂量方案
|
|
JOP20190191A1
(ar)
|
2017-02-22 |
2019-08-08 |
Astrazeneca Ab |
وحدات شجرية علاجية
|
|
JP7216006B2
(ja)
|
2017-03-22 |
2023-01-31 |
ジェネンテック， インコーポレイテッド |
ヒドロゲル架橋ヒアルロン酸プロドラッグ組成物及び方法
|
|
JOP20190245A1
(ar)
|
2017-04-20 |
2019-10-15 |
Novartis Ag |
أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
|
|
US20200323962A1
(en)
*
|
2017-09-19 |
2020-10-15 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Lipophilic peptide prodrugs
|
|
EP3684785B1
(en)
|
2017-09-19 |
2024-10-02 |
Technische Universität München |
N-methylated cyclic peptides and their prodrugs
|
|
RU2020126774A
(ru)
|
2018-01-12 |
2022-02-14 |
ПРОЛИНКС ЭлЭлСи |
Протокол для сведения к минимуму токсического воздействия комбинированных доз и визуализирующий агент для подтверждения
|
|
EP3765096A1
(en)
|
2018-03-12 |
2021-01-20 |
Boston Scientific Scimed Inc. |
Scavenging methods, and scavenging system for radiocontrast agents
|
|
EP3773681A1
(en)
|
2018-03-28 |
2021-02-17 |
Ascendis Pharma A/S |
Conjugates
|
|
CN111918665B
(zh)
|
2018-03-28 |
2024-11-26 |
阿森迪斯药物肿瘤股份有限公司 |
Il-2缀合物
|
|
PT3793587T
(pt)
|
2018-05-18 |
2025-07-25 |
Ascendis Pharma Bone Diseases As |
Dose inicial de conjugados de pth
|
|
US12071517B2
(en)
|
2018-07-19 |
2024-08-27 |
Starpharma Pty Ltd. |
Therapeutic dendrimer
|
|
MX2021000677A
(es)
|
2018-07-19 |
2021-03-25 |
Starpharma Pty Ltd |
Dendrimero terapeutico.
|
|
US20210330798A1
(en)
|
2018-09-26 |
2021-10-28 |
Ascendis Pharma A/S |
Treatment of infections
|
|
US20210330807A1
(en)
|
2018-09-26 |
2021-10-28 |
Ascendis Pharma A/S |
Novel hydrogel conjugates
|
|
US20210338834A1
(en)
|
2018-09-26 |
2021-11-04 |
Ascendis Pharma A/S |
Degradable hyaluronic acid hydrogels
|
|
AR116566A1
(es)
|
2018-10-03 |
2021-05-19 |
Novartis Ag |
Administración sostenida de polipéptidos similares a la angiopoyetina 3
|
|
CA3125541A1
(en)
|
2019-01-04 |
2020-07-09 |
Ascendis Pharma Oncology Division A/S |
Minimization of systemic inflammation
|
|
EP3906018A1
(en)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Induction of sustained local inflammation
|
|
MX2021007706A
(es)
|
2019-01-04 |
2021-08-05 |
Ascendis Pharma Oncology Div A/S |
Conjugados de agonistas de receptor de reconocimiento de patron.
|
|
EP3906032A1
(en)
|
2019-01-04 |
2021-11-10 |
Ascendis Pharma Oncology Division A/S |
Sustained local drug levels for innate immune agonists
|
|
BR112021014581A2
(pt)
|
2019-02-11 |
2021-12-14 |
Ascendis Pharma Bone Diseases As |
Formulações farmacêuticas líquidas de conjugados de pth
|
|
WO2020165081A1
(en)
|
2019-02-11 |
2020-08-20 |
Ascendis Pharma Growth Disorders A/S |
Dry pharmaceutical formulations of cnp conjugates
|
|
KR20210150496A
(ko)
*
|
2019-04-05 |
2021-12-10 |
프로린크스 엘엘시 |
개선된 컨쥬게이션 링커
|
|
CN114126638A
(zh)
*
|
2019-04-26 |
2022-03-01 |
普罗林科斯有限责任公司 |
缓慢释放的细胞因子偶联物
|
|
WO2020254617A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pk properties
|
|
WO2020254612A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
|
|
WO2020254611A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 conjugates
|
|
WO2020254613A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
|
|
WO2020254607A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Anti-ctla4 compounds with localized pd properties
|
|
WO2020254609A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma Oncology Division A/S |
Tyrosine kinase inhibitor conjugates
|
|
EP3986477A1
(en)
*
|
2019-06-21 |
2022-04-27 |
Ascendis Pharma A/S |
CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS
|
|
KR20220074897A
(ko)
*
|
2019-09-30 |
2022-06-03 |
베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 |
단백질-거대분자 접합체 및 이의 사용 방법
|
|
IL294357A
(en)
|
2020-01-13 |
2022-08-01 |
Ascendis Pharma Bone Diseases As |
Hypoparathyroidism treatment
|
|
US20230241217A1
(en)
|
2020-05-04 |
2023-08-03 |
Ascendis Pharma A/S |
Hydrogel irradiation
|
|
TW202210502A
(zh)
|
2020-06-03 |
2022-03-16 |
丹麥商阿森迪斯腫瘤製藥有限公司 |
新穎il-2序列及其用途
|
|
WO2022043493A1
(en)
|
2020-08-28 |
2022-03-03 |
Ascendis Pharma Oncology Division A/S |
Glycosylated il-2 proteins and uses thereof
|
|
MX2023003540A
(es)
|
2020-09-28 |
2023-04-21 |
Ascendis Pharma Bone Diseases As |
Mejora del bienestar fisico y mental de los pacientes con hipoparatiroidismo.
|
|
BR112023018802A2
(pt)
|
2021-04-01 |
2023-10-31 |
Ascendis Pharma As |
Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação
|
|
IL311539A
(en)
|
2021-09-22 |
2024-05-01 |
Ascendis Pharma Bone Diseases As |
Long-acting pth compound treatments
|
|
US20250017948A1
(en)
*
|
2021-10-19 |
2025-01-16 |
The United States Government As Represented By The Department Of Veterans Affairs |
Cannabinoid compositions for gastroesophageal disorders
|
|
CA3238942A1
(en)
|
2021-12-13 |
2023-06-22 |
Vibeke MILLER BREINHOLT |
Cancer treatments with tlr7/8 agonists
|
|
AU2022413318A1
(en)
|
2021-12-13 |
2024-05-16 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
|
US20250195617A1
(en)
|
2022-05-23 |
2025-06-19 |
Ascendis Pharma Growth Disorders A/S |
Liquid Pharmaceutical Formulations of CNP Compounds
|
|
CN114874624B
(zh)
*
|
2022-05-27 |
2023-04-07 |
深圳市博致远科技有限公司 |
一种导热吸波室温固化硅橡胶产品及其制备方法
|
|
CN120752051A
(zh)
|
2022-11-02 |
2025-10-03 |
阿森迪斯药物骨疾病股份有限公司 |
包含两种pth化合物的pth治疗方案
|
|
WO2024104922A1
(en)
|
2022-11-14 |
2024-05-23 |
Ascendis Pharma Growth Disorders A/S |
Method of improving skeletal muscle function
|
|
TW202430223A
(zh)
|
2023-01-05 |
2024-08-01 |
丹麥商阿仙帝斯眼科製藥有限公司 |
用於治療眼部病症之藥物結合物
|
|
TW202434299A
(zh)
|
2023-01-05 |
2024-09-01 |
丹麥商阿仙帝斯製藥公司 |
製造水凝膠微球之方法
|
|
AU2024232757A1
(en)
|
2023-03-06 |
2025-08-21 |
Ascendis Pharma A/S |
Drug compounds comprising albumin-binding moieties
|
|
WO2024184351A1
(en)
|
2023-03-06 |
2024-09-12 |
Ascendis Pharma A/S |
Compounds of drugs with an albumin binding moiety
|
|
AU2024233842A1
(en)
|
2023-03-06 |
2025-09-04 |
Ascendis Pharma A/S |
Multi-albumin binding compounds
|
|
WO2024194300A1
(en)
|
2023-03-20 |
2024-09-26 |
Ascendis Pharma Growth Disorders A/S |
Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
|
|
AU2024270185A1
(en)
|
2023-05-09 |
2025-11-06 |
Ascendis Pharma Oncology Division A/S |
Novel cancer treatments with il-2 conjugates
|
|
WO2025051711A1
(en)
|
2023-09-04 |
2025-03-13 |
Ascendis Pharma Bone Diseases A/S |
Pth treatment of chronic kidney disease
|
|
WO2025208117A1
(en)
*
|
2024-03-29 |
2025-10-02 |
Maha Therapeutics, Inc. |
Cleavable ester compounds and uses thereof
|